FDA staff cautious on AstraZeneca, Bristol diabetes drug
LONDON Dec 10 (Reuters) - U.S. Food and Drug Administration staff said on Tuesday they were wary about the benefits versus the risks of AstraZeneca and Bristol-Myers Squibb's new diabetes drug dapagliflozin in documents posted on the agency's website.
It was not possible to conclude with confidence that the purported cardiovascular benefit associated with using the drug outweighed "the observed imbalance in specific malignancies or potential liver toxicity risks", they said.
The briefing documents were posted ahead of an advisory committee meeting on Thursday.
- Exclusive: Radar data suggests missing Malaysia plane deliberately flown way off course - sources
- Investigators focus on foul play behind missing plane-sources |
- Russia ships troops into Ukraine, repeats invasion threat |
- Search for Malaysian plane may extend to Indian Ocean - U.S |
- Russia blocks internet sites of Putin critics